VEGFA and thyroid gland carcinoma: In a phase I study with cabozantinib in metastatic differentiated thyroid cancer, a partial response was reported in 8 out of 15 patients who failed standard radioactive iodine therapy and in 5 out of 8 patients previously treated with VEGF pathway inhibitors [54].